FibroGen, Inc. (NASDAQ:FGEN) Expected to Announce Quarterly Sales of $36.60 Million

Equities analysts predict that FibroGen, Inc. (NASDAQ:FGENGet Rating) will post sales of $36.60 million for the current quarter, according to Zacks. Four analysts have made estimates for FibroGen’s earnings, with the highest sales estimate coming in at $42.72 million and the lowest estimate coming in at $28.00 million. FibroGen posted sales of $24.36 million in the same quarter last year, which suggests a positive year over year growth rate of 50.2%. The firm is expected to issue its next earnings report on Monday, January 1st.

On average, analysts expect that FibroGen will report full year sales of $179.24 million for the current financial year, with estimates ranging from $150.00 million to $194.79 million. For the next year, analysts anticipate that the firm will post sales of $203.95 million, with estimates ranging from $154.00 million to $288.42 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow FibroGen.

FibroGen (NASDAQ:FGENGet Rating) last released its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.16. The firm had revenue of $60.80 million for the quarter, compared to the consensus estimate of $28.76 million. FibroGen had a negative return on equity of 109.09% and a negative net margin of 109.22%. The company’s revenue for the quarter was up 58.3% on a year-over-year basis. During the same period last year, the business posted ($0.78) EPS.

Several research firms have recently weighed in on FGEN. Zacks Investment Research raised FibroGen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 10th. StockNews.com assumed coverage on shares of FibroGen in a report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, The Goldman Sachs Group reduced their price objective on shares of FibroGen from $9.00 to $8.00 and set a “sell” rating for the company in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.29.

FGEN stock opened at $9.22 on Friday. The stock has a market cap of $860.21 million, a P/E ratio of -3.03 and a beta of 0.91. FibroGen has a twelve month low of $7.81 and a twelve month high of $30.12. The business’s 50-day moving average price is $10.76 and its 200-day moving average price is $12.80.

A number of hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC lifted its position in shares of FibroGen by 2,622.1% during the third quarter. Cubist Systematic Strategies LLC now owns 231,544 shares of the biopharmaceutical company’s stock worth $2,366,000 after purchasing an additional 223,038 shares in the last quarter. Citigroup Inc. grew its position in FibroGen by 13.9% during the 3rd quarter. Citigroup Inc. now owns 190,075 shares of the biopharmaceutical company’s stock worth $1,943,000 after purchasing an additional 23,225 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in FibroGen by 0.5% in the third quarter. Farallon Capital Management LLC now owns 1,446,212 shares of the biopharmaceutical company’s stock worth $14,780,000 after purchasing an additional 7,285 shares in the last quarter. Squarepoint Ops LLC lifted its position in FibroGen by 277.5% during the 3rd quarter. Squarepoint Ops LLC now owns 74,222 shares of the biopharmaceutical company’s stock worth $759,000 after acquiring an additional 54,561 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of FibroGen by 17.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 69,170 shares of the biopharmaceutical company’s stock valued at $975,000 after buying an additional 10,521 shares during the last quarter. 77.35% of the stock is currently owned by hedge funds and other institutional investors.

FibroGen Company Profile (Get Rating)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Read More

Get a free copy of the Zacks research report on FibroGen (FGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.